Cytotoxicity Reduction
Cytotoxicity Reduction - Related Videos
08:22
Cytotoxicity Assays with Zebrafish Cell Lines
0 Views •
Cited by 7 •
2023
This protocol presents commonly used cytotoxicity assays (Alamar Blue [AB], CFDA-AM, Neutral Red, and MTT assays) adapted for the assessment of cytotoxicity in zebrafish embryo (ZEM2S) and liver (ZFL) cell lines in 96-well plates.
03:00
An Assay to Evaluate Immunodominance in Cytotoxic T Lymphocyte Responses
0 Views •
2025
The video showcases a flow cytometry-based assay for assaying immunodominance in cytotoxic T lymphocytes or CTL responses. Injected fluorescent target cells exhibit varying fluorescence corresponding to immunogenic epitopes. Post-spleen collection and sorting reveal a reduction in high-intensity fluorescent cells, confirming immunodominance in CTL responses.
03:11
Oxidation-Reduction Reactions
0 Views •
2020
Oxidation–Reduction Reactions Earth’s atmosphere contains about 20% molecular oxygen, O2, a chemically reactive gas that plays an essential role in the metabolism of aerobic organisms and in many environmental processes that shape the world. The term oxidation was originally used to describe chemical reactions involving O2, but its meaning has evolved to refer to a broad and important reaction class known as oxidation–reduction (redox) reactions. Some redox reactions involve the transfer of...
04:45
An Immunological Technique to Monitor Adjuvant-Mediated Cytotoxic T Lymphocyte Generation
0 Views •
2025
The video demonstrates an immunological method to monitor in vivo adjuvant-induced cytotoxic T lymphocyte or CTL production. A mouse is pre-injected with genetically engineered, proliferative dye-stained donor CD8+ T lymphocytes. Subcutaneous injection of ovalbumin with adjuvants generates cytotoxic CD8+ T lymphocytes that are identified post-harvesting through immunostaining and flow cytometry.
02:58
Evaluating Cytotoxicity and Membrane Integrity in Lung Slices via Lactate Dehydrogenase Assay
0 Views •
2025
This video demonstrates the lactate dehydrogenase, LDH assay to measure the cytotoxic effect of a test substance and its effect on the membrane integrity in human precision-cut lung slices. The assay provides a quantitative measure of cell death or damage in the sample.
FAQs
Lowering exposure concentration or shortening duration can reduce harmful cellular effects, but the change must remain compatible with the intended function of the system. These variables help researchers distinguish whether toxicity is associated with dose, contact time, or both. Testing them systematically supports safer design decisions for materials, compounds, and engineered systems.
Modifying material chemistry or surface properties can improve cellular compatibility without requiring removal of the material’s intended role. Such changes target how cells encounter the engineered surface or formulation, while preservation of function remains a design constraint. In bioengineering, this balance is important for developing biomaterials, implants, delivery systems, and scaffolds that perform as intended.
Cell-viability, membrane-integrity, metabolic, and apoptosis assays reveal different aspects of cellular response, so no single readout fully describes cytotoxicity reduction. Comparing these outcomes helps identify whether a formulation or device is associated with fewer surviving cells, damaged membranes, altered metabolism, or programmed cell death. The combined evidence guides refinement of the design.
A basic workflow begins by identifying potentially toxic components, then varying exposure concentration or duration and, when appropriate, modifying material chemistry or surface properties. Researchers next measure cellular responses with viability, membrane-integrity, metabolic, or apoptosis assays. They use the findings to refine the formulation or device while checking that its intended function is preserved.
Cytotoxicity reduction is especially relevant when bioengineered systems contact living cells or are intended for biomedical use. Applications named in this context include drug-delivery systems, biomaterials, implants, tissue-engineering scaffolds, and in vitro models. In each case, reducing harmful cellular responses can support safer designs and make experimental or translational conclusions more reliable.
Reducing adverse cellular responses helps researchers determine whether an observed outcome reflects the intended behavior of a material, compound, or engineered system rather than unwanted cellular harm. This distinction strengthens the reliability of in vitro models and supports more dependable translation of bioengineering findings toward biomedical designs, including delivery platforms, implants, and tissue-engineering systems.